ACRS:NSD-Aclaris Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.31

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

0.33M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.24B 20.76 16.02
MRNA Moderna, Inc

N/A

USD43.20B N/A N/A
SGEN Seagen Inc

N/A

USD29.62B 65.69 65.81
ALXN Alexion Pharmaceuticals, Inc

N/A

USD26.98B 28.36 26.40
RPRX Royalty Pharma plc

N/A

USD25.62B 22.60 9.61
BGNE BeiGene, Ltd

N/A

USD25.22B N/A N/A
BNTX BioNTech SE

N/A

USD24.53B -99,999.99 N/A
GMAB Genmab A/S

N/A

USD23.24B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ACRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 75.13% 80% B- 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.13% 80% B- 86% B
Trailing 12 Months  
Capital Gain 101.83% 79% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 101.83% 79% C+ 88% B+
Trailing 5 Years  
Capital Gain -85.85% 24% F 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.85% 24% F 7% F
Average Annual (5 Year Horizon)  
Capital Gain -24.57% N/A N/A 7% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.57% N/A N/A 7% F
Risk Return Profile  
Volatility (Standard Deviation) 57.38% N/A N/A 19% F
Risk Adjusted Return -42.82% N/A N/A 16% F
Market Capitalization 0.14B 34% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.25 58% F 40% F
Price / Cash Flow Ratio -1.47 19% F 62% D-
EV/EBITDA 0.05 86% B 98% A+
Management Effectiveness  
Return on Equity -90.46% 34% F 13% F
Return on Invested Capital -58.77% 54% F 17% F
Return on Assets -27.72% 49% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.27 69% D+ 63% D
Short Percent 1.50% 85% B 69% D+
Beta 1.15 68% D+ 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector